Global Medical Cannabis Market, by Sclerosis, 2018-2027

Growth Outlook

• The 2027 portion of the Global Medical Cannabis Market, by Sclerosis, 2018 market is on a steady long-term growth path. Segment value stands at roughly USD 4208 Mn in 2026 and is projected to reach USD 4867 Mn by 2027 — a gain of about 16% over the forecast period, translating to a CAGR in the double digits.
• Medical cannabis, also known as medical marijuana, has been gaining recognition as a potential treatment option for various medical conditions. One such condition is sclerosis, a chronic degenerative disease that affects the central nervous system.
• What the regional split looks like (2026): Americas leads, holding roughly 73% of segment value — the single largest regional share. Europe is the second-largest contributor. Asia-Pacific and Middle East & Africa make up the remainder, in descending order.
• By 2027, Americas alone is expected to reach USD 3420 Mn, with Europe at USD 1074 Mn.

Market Dynamics

Medical cannabis, also known as medical marijuana, has been gaining recognition as a potential treatment option for various medical conditions. One such condition is sclerosis, a chronic degenerative disease that affects the central nervous system. Sclerosis is a term used to describe a hardening or stiffening of tissues in the body. Multiple sclerosis (MS) is the most common type of sclerosis, where the protective covering of nerve fibers in the brain and spinal cord are damaged. This leads to a disruption in communication between the brain and other areas of the body, resulting in various neurological symptoms such as muscle weakness, numbness, and difficulties with balance and coordination. There is no known cure for MS, and current treatments aim to manage symptoms and slow disease progression. However, many individuals with MS experience adverse side effects from these treatments. As a result, there is a growing demand for alternative and more natural treatment options, leading to the rise in demand for medical cannabis as a potential therapeutic option. Cannabis contains over 100 different chemical compounds called cannabinoids, with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) being the most well-known.

These cannabinoids interact with the endocannabinoid system in the body, which plays a crucial role in regulating various bodily functions, including the immune system and nervous system. Studies have shown that THC and CBD have anti-inflammatory and neuroprotective properties, making them potential candidates for the treatment of MS. It is believed that these compounds may help reduce inflammation and pain while also protecting nerve cells from damage. In addition to its potential therapeutic benefits, medical cannabis also offers a more natural and holistic approach to managing MS symptoms. Many individuals with MS prefer medical cannabis as it does not have the same level of adverse side effects as traditional treatments. However, the demand for medical cannabis for MS treatment has also sparked debates and discussions, with some questioning its effectiveness, safety, and legal status. As a result, further research and clinical trials are needed to fully understand the potential benefits and risks of using medical cannabis for MS. In conclusion, the demand for medical cannabis for sclerosis is on the rise as individuals seek alternative and more natural treatment options for this chronic condition.

While more research is needed, it is clear that medical cannabis has the potential to offer relief for those living with MS. As the global medical cannabis market continues to grow, it is important for regulations and guidelines to be in place to ensure its safe and effective use for those who need it.

Research Methodology

Figures reflect Wantstats’ original market research and forecasting models, compiled as part of the Wantstats research archive and published in 2024.